Duopharma Biotech BhdXKLS:7148 83 Gross Margin % is 39.25% as of Mar. 2026, which is 2% below its 10-year median of 40.05. GuruFocus rates XKLS:7148 with a GF Score™ of 83/100 and a GF Value™ of RM1.52 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 935 Drug Manufacturers companies, Duopharma Biotech Bhd ranks worse than 65.13% on this metric.
XKLS:7148's Gross Margin % is ranked worse than 65.13% of 935
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs XKLS:7148: 40.05
Duopharma Biotech Bhd had a gross margin of 39.25% for the quarter that ended in Mar. 2026 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for Duopharma Biotech Bhd was -1.40% per year.
Duopharma Biotech Bhd (XKLS:7148) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Duopharma Biotech Bhd had a gross margin of 39.25% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Duopharma Biotech Bhd Gross Margin % Related Terms
Duopharma Biotech Bhd Gross Margin % Historical Data
* Premium members only.
The historical data trend for Duopharma Biotech Bhd's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:7148 vs ZTS, UTHR, VTRS: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Duopharma Biotech Bhd's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Duopharma Biotech Bhd Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Duopharma Biotech Bhd's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Duopharma Biotech Bhd's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Duopharma Biotech Bhd (XKLS:7148) has a Gross Margin % of 39.25% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Duopharma Biotech Bhd and its competitors. This is near median its historical median of 40.05. Over the past decade, Duopharma Biotech Bhd's Gross Margin % has ranged from 37.06 to 46.06. According to the industry distribution chart, Duopharma Biotech Bhd ranks #609 out of 935 companies in the Drug Manufacturers industry, placing it in the top 65.1%.
Is Duopharma Biotech Bhd's Gross Margin % too high?
Duopharma Biotech Bhd's current Gross Margin % of 39.25% is near median its 10-year median of 40.05. Over the past 10 years, this metric has ranged from a low of 37.06 to a high of 46.06. The Drug Manufacturers industry median Gross Margin % is 48.54. Duopharma Biotech Bhd's value of 39.25% is 19.1% below this industry median. Based on the distribution chart, Duopharma Biotech Bhd ranks #609 out of 935 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Duopharma Biotech Bhd has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Duopharma Biotech Bhd's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Duopharma Biotech Bhd ranks #609 out of 935 companies for Gross Margin %. This places Duopharma Biotech Bhd in the lower half of its industry. The industry median Gross Margin % is 48.54. Duopharma Biotech Bhd's value of 39.25% is 19.1% below this benchmark. Historically, Duopharma Biotech Bhd's own Gross Margin % has ranged from 37.06 to 46.06 over the past decade. While the company's 10-year median is 40.05 vs. the industry median of 48.54, Duopharma Biotech Bhd has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Duopharma Biotech Bhd's current Gross Margin % of 39.25% is 19.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Duopharma Biotech Bhd and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Duopharma Biotech Bhd's current Gross Margin % is 39.25%, which is near median its own 10-year median of 40.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duopharma Biotech Bhd stock overvalued right now?
Based on GuruFocus' analysis, Duopharma Biotech Bhd (XKLS:7148) is currently considered Modestly Undervalued. The stock's GF Value™ is RM1.52, compared to a current price of RM1.20 — trading 21.1% below its estimated fair value. The current Gross Margin % is 39.25%, which is near median its 10-year median of 40.05 and 19.1% below the Drug Manufacturers industry median of 48.54. Duopharma Biotech Bhd's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Duopharma Biotech Bhd (XKLS:7148), the current Gross Margin % is 39.25% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Duopharma Biotech Bhd (XKLS:7148) Overvalued in 2026?
Based on GuruFocus' analysis, Duopharma Biotech Bhd stock appears to be undervalued.
The current stock price of RM1.20 is trading 21.1% below its estimated GF Value™ of RM1.52.
GuruFocus considers Duopharma Biotech Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:7148:
Gross Margin %: 39.25% (near median its 10-year median of 40.05)
GF Value™: RM1.52 vs. price of RM1.20 (21.1% below fair value)
Industry Position: 19.1% below the Drug Manufacturers median (#609 of 935)
No single metric tells the full story. See the XKLS:7148 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. The company develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.
83GF Score
Get the complete analysis for XKLS:7148
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7148 has been successfully added to your 
